Aurora Cannabis Inc. (TSX:ACB) Acquires Another Company: Why This Is Good News for Investors

Aurora Cannabis Inc (TSX:ACB) continues to wheel and deal as it looks to expand its reach and capabilities in the industry.

| More on:

Aurora Cannabis Inc. (TSX:ACB) is going to purchase yet another company. In a much smaller acquisition than its $3.2 billion purchase of MedReleaf Corp. (TSX:LEAF), Aurora is going to acquire Anandia Laboratories for a price tag of $115 million. The Vancouver-based company will provide Aurora with valuable research and development and testing services.

Not a lot of green on the balance sheet

The deal to purchase Anandia is an all-stock acquisition, as Aurora has a limited supply of cash on its balance sheet. In the company’s most recent quarter, it had just $231 million in cash and equivalents, so this acquisition, small as it may be, would have depleted about half that amount.

While the all-stock deal makes it easy to arrange payment, investors will feel the impact of more dilution, as the company will once again issue more shares in order to fund the transaction.

Positioning itself for strong growth ahead

The acquisition of MedReleaf and Anandia tell me that Aurora is wisely trying to focus on the opportunities that exist in medical marijuana as well as the potential that exists in the recreational pot market.

While recreational marijuana is certainly all the rage this year, the more significant growth opportunities may actually lie in the medical market. Many studies have found marijuana to be effective for pain relief and in treating various types of ailments.

The challenge for cannabis companies is proving that there are some very significant advantages to using marijuana for medical purposes. It hasn’t helped that studies on cannabis are limited, as it is still categorized as a Schedule I drug in the U.S., which makes researching it there very difficult.

However, as we see some more studies and some more definitive results when it comes to the illnessees that cannabis can treat, the growth opportunities could easily exceed the potential that exists in the recreational market. Investors only need to look at the opioid problems south of the border as an example of this.

It may be a longer-term play, but focusing on medical marijuana could provide Aurora with significant growth opportunities over the long term.

Are more acquisitions on the way?

With more and more pot stocks on the exchanges, there’s continually more opportunities for acquisitions. New cannabis companies face big obstacles when it comes to establishing a brand and trying to wrestle away market share from more well-known cannabis companies.

The fragmentation that exists in the industry along with the challenges that small companies face makes it inevitable that we’ll see more acquisitions in the future. Given what we’ve seen so far, I wouldn’t be surprised if Aurora isn’t done.

Bottom line

This latest acquisition by Aurora isn’t going to break its bank or its stock price, and in the long term, a focus on medical marijuana could pay off significantly. Aurora’s share price has struggled since the start of the year, and investors may want to keep this one on their watch list as a further dip in price could make the stock a very appealing buy.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Investing

Asset Management
Investing

2 Soaring Stocks to Hold for the Next 20 Years

These two stocks are poised to continue outperforming the broader equity markets.

Read more »

Hand Protecting Senior Couple
Retirement

These 2 Dividend ETFs Are a Retiree’s Best Friend

These two dividend ETFs could provide retirees with a diversified and stable income stream, while providing some price appreciation.

Read more »

TFSA (Tax-Free Savings Account) on wooden blocks and Canadian one hundred dollar bills.
Tech Stocks

Shopify: A Must-Have Growth Stock for Your TFSA Now (and the Next 10 Years)

Shopify (TSX:SHOP) stock isn't just a top growth company, it's a titan worth owning in your decades-long TFSA fund.

Read more »

Investing

Have $1,000? Here Are the Best Stocks to Buy Right Now

These TSX stocks have solid growth potential and will likely deliver above-average returns in the long term.

Read more »

cloud computing
Tech Stocks

Best Stock to Buy Right Now: Manulife vs CIBC

Want the best stocks? These two are certainly the best options. But which is the better buy?

Read more »

ETF stands for Exchange Traded Fund
Dividend Stocks

How to Earn $2,000 in Passive Income in 2025 With Less Than $51,000 in Savings

You can invest in Canadian high yield stocks via the Vanguard FTSE Canadian High Yield Dividend ETF (TSX:VDY).

Read more »

Asset Management
Investing

Where Will Restaurant Brands International Stock Be in 1/3/5 Years?

Let's dive into where Restaurant Brands (TSX:QSR) could be headed over the near to medium term, shall we?

Read more »

profit rises over time
Tech Stocks

4 Reasons to Buy Constellation Software Stock Like There’s No Tomorrow

Constellation Software stock continued its climb upwards after recent earnings, and this only adds to its appeal.

Read more »